17,261 trials
Acute Otitis Media
Primary: Area Under the Curve From Time Zero to 72 Hours (AUC72Hours) — 12173.023; 7950.949 ng*hr/ml
Breast Cancer
Primary: Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) — 6; 7…
Prostatic Hypertrophy, Benign
Primary: Baseline-adjusted Least Squared (LS) Means of Peak Urinary Flow (Qmax) at 3 Months After Surgery or Last Observation Carried Forward (LOCF) — 8.3; 9.4; 23.1; 25.7…
Postmenopause · Hypertension · Pre-Hypertension
Primary: Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population — -1.03…
Congestive Heart Failure
Primary: Percentage of Subjects Classified as "Not Worsened" for Changes in the Minnesota Living With Heart Failure Questionnaire and Six-minute Walk Distance Between Periods of…
Hypercholesterolemia · Statin-Associated Myopathy
Primary: Withdrawal of Therapy Due to Muscle Symptoms That Are Either Intolerable and/or Associated With a Creatine Kinase(CK) >500 — 2; 1 Participants
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Tobacco Use Disorder
Primary: Smoking Abstinence at 26 Weeks — 21; 22 participants — p=>.05
Depression · Depressive Disorder
Primary: Antidepressant Response, Defined as a Hamilton Depression Rating Scale Score Relative Decrease of 50 % or More and a Final Score < 10 — 11; 11 participants
Infections, Gram-Positive Bacterial · Abscess · Burns
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 66; 66; 6; 3 participants — p=0.5289
Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 — -0.537; -0.174; 0.309 Percent change — p=0.641
Meningitis · Meningococcal Infection
Primary: Percentage of Participants With a ≥8 Antibody Titers as Measured by Serum Bactericidal Assay Human Complement (SBA-HC) After Each Vaccination. — 38; 44; 33; 40…
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Primary: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 — 36; 14 Participants
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score